Florham Park-based Cellectar Biosciences Inc., a late-stage clinical biopharmaceutical company, said that, effective Nov. 21, Shane Lea has been named the company’s chief commercial officer.
Lea most recently served as senior vice president, hematology, at TG Therapeutics, where he oversaw the sales, marketing and analytics teams for the hematology franchise. Prior to TG Therapeutics, Lea served as vice president, hematology myeloid franchise at Celgene-BMS, where he was responsible for building and leading commercial teams supporting the successful launches of Revlimid in mantle cell, marginal zone and follicular lymphoma. He also oversaw the successful product launches for IDHIFA, INREBIC, REBLOZYL and ONUREG.
Earlier in his career, Lea served in a variety of commercial leadership roles across biotech and multinational pharmaceutical companies, including: Allos Therapeutics, ImClone Systems, Abraxis Bioscience, Sanofi-Aventis, Aventis Oncology, Parke-Davis and Novartis.
“Mr. Lea’s exceptional track record for rapidly constructing cost-efficient commercial infrastructure, creating innovative go-to-market strategies and developing high-performance teams for successful product launches provides the necessary experience and skill sets that Cellectar requires. As we prepare for the approval of iopofosine, his professional background is ideally suited for our newly created position of chief commercial officer and we look forward to his leadership,” said James Caruso, CEO and president of Cellectar.
Lea added: “I’m thrilled to join this committed and talented team at this exciting point. There is a tremendous need to improve upon the standard of care for patients with Waldenstrom’s macroglobulinemia, and I look forward to supporting those patients by bringing this important product to market. I am also excited about Cellectar’s Phospholipid Drug Conjugate platform and the potential application to create differentiated oncology products that can address patient unmet needs.”
